What it sells
Medicinal Chemistry powered by Machine Learning
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma business development / R&D leaders signing partnership deals.
Workflow: what inputs become what output?
Partner picks targets and assay cascade; PostEra drives AI-enabled small-molecule discovery to development candidate; partner and PostEra decide who sponsors IND-enabling studies. Proton platform closes design-make-test loop.
Economics: what it saves and how it charges
Co-discovery collaborations paying milestones and royalties (Pfizer collaboration expanded to $610M); also own pipeline in women's health with fertility programs sold to Merck KGaA.
Distribution: how it reaches customers
Direct business development (partnerships@postera.ai).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.